Genital warts (condyloma acuminata) are soft skin-coloured or pinkish growths that appear on the moist skin and mucous membranes of the genital and anal region. They are caused by human papillomavirus, specifically the low-risk types 6 and 11, which together account for about ninety percent of all visible genital warts. The virus infects the surface skin cells, causes them to multiply abnormally, and over weeks to months produces the characteristic cauliflower-like clusters or small flat bumps.

Genital warts are common. At any given time around one percent of sexually active Indian adults have visible warts, and the lifetime risk of being exposed to a wart-causing HPV type is much higher because the virus is widespread in the population. The bumps are usually painless, sometimes itchy, and almost always cosmetically distressing rather than medically dangerous. They do not threaten fertility, do not affect general health, and in most women clear up with treatment within a few months.

The key reassurance to hold at the start is that genital warts are neither rare nor a sign of moral failing. They are a common skin manifestation of a common virus, and the right framing is medical management rather than shame. For the broader context of HPV see HPV in India: Types, Symptoms, Diagnosis, and Treatment Explained.

There are more than a hundred HPV types, and they fall broadly into low-risk and high-risk groups. The low-risk types — predominantly 6 and 11 — cause visible genital warts but do not cause cancer. The high-risk types — predominantly 16 and 18, with smaller contributions from 31, 33, 45, 52 and 58 — do not usually cause visible warts but are responsible for almost all cervical cancer and significant proportions of anal vulvar vaginal and oropharyngeal cancers. The two groups are biologically and clinically distinct.

What this means for a woman with genital warts is that the warts themselves will not turn into cancer. Treating the warts removes the visible disease but does not change cancer risk one way or the other. The cancer risk is set by whether she also carries one of the high-risk HPV types, which is a separate question answered by Pap smear and HPV DNA testing of the cervix. Co-infection with both low-risk and high-risk HPV types is common because both are spread the same way, so a woman with visible warts should ensure her cervical screening is up to date — see Cervical Cancer in India: Screening, Treatment, and the Tests That Save Lives.

The take-home is simple. Visible warts are caused by HPV 6 and 11, are not cancer, will not become cancer, and are treatable. The cancer-risk question is separate, is answered by cervical screening, and is reduced by the HPV vaccine, which protects against the high-risk types as well as the wart-causing types.

Genital warts spread by skin-to-skin contact during vaginal, anal or oral sex with a partner who carries the wart-causing HPV. Penetration is not required; close genital skin-to-skin contact is enough. The virus enters through tiny breaks in the skin or mucous membrane that occur naturally during sex, then sets up infection in the surface cells. After exposure the incubation period before visible warts appear ranges from a few weeks to many months, sometimes more than a year, which makes it difficult to identify the exact moment or partner of transmission.

Condoms reduce but do not eliminate transmission. The wart-causing HPV can be present on skin areas not covered by the condom (the base of the penis, scrotum, vulva, perineum and anal region), so transmission is still possible even with consistent condom use. Studies suggest condoms reduce transmission by roughly fifty to seventy percent rather than the near-total reduction seen with other STIs. Condoms remain worth using because partial protection is meaningful and because they reduce other STIs at the same time.

A person can transmit HPV without having any visible warts. The virus is often present on apparently normal skin, and many people who carry it never develop visible warts themselves. This means a partner who has never had visible warts can still transmit the infection, and it also means that the appearance of warts in one partner does not necessarily mean the other partner has been unfaithful — the infection may have been acquired years earlier and stayed latent until the visible warts appeared.

Genital warts in women typically appear as small soft pinkish or skin-coloured bumps on the vulva (the outer genital area), and they may stay small and individual or cluster together into the classic cauliflower-like patches. The texture is usually soft rather than hard, and the surface is often irregular or papillary rather than smooth. Common locations include the labia majora and minora, the area around the vaginal opening, the perineum (between the vagina and anus), the anus and perianal skin, and inside the vagina and on the cervix where they are visible only on speculum examination.

Warts can also appear in the mouth and throat after oral sex with an infected partner, although this is less common. Most warts are painless, but they can become itchy, irritated by clothing or hygiene products, or occasionally bleed if rubbed or scratched. Larger clusters may cause discomfort during sex or with hygiene. The classic cauliflower appearance is recognisable but smaller earlier warts may look like simple skin tags or small flat bumps and can be missed without close inspection.

Any new bump in the genital area that persists for more than a couple of weeks deserves an OB-GYN or dermatologist look. Self-diagnosis is unreliable because several other conditions — skin tags, molluscum contagiosum, cysts, normal anatomical variation including vulvar papillomatosis — can look similar. A proper examination settles the question quickly and is the first step to treatment.

Diagnosis of genital warts is in most cases a clinical visual examination by an OB-GYN or dermatologist, and a confident eye-only diagnosis is usually sufficient for typical cauliflower-like external warts. The doctor inspects the vulva, perineum and anal area with good lighting, and a speculum examination is added to look at the vaginal walls and cervix. The whole visit usually takes ten to fifteen minutes and is comfortable apart from the speculum step. Costs at private OB-GYN clinics range from five hundred to fifteen hundred rupees for the consultation, while NACO-supported STI clinics offer the assessment free and confidentially.

When the appearance is uncertain, the acetic acid test is a simple bedside aid. A dilute white vinegar solution applied to the suspicious area turns wart tissue temporarily white (acetowhitening), which helps distinguish warts from normal skin. The test is not specific enough to use alone but is useful alongside the visual exam. For lesions that look atypical, are unusually pigmented, are large or ulcerated, or do not respond to treatment, a biopsy under local anaesthesia is taken and sent for histopathology to rule out high-grade dysplasia or malignancy (costs around eight hundred to two thousand five hundred rupees).

Because cervical involvement is possible and because co-infection with high-risk HPV types is common, any woman with external genital warts should also have a Pap smear (around three hundred to one thousand five hundred rupees in private labs, free at government screening programmes) and ideally an HPV DNA test (around one thousand five hundred to four thousand rupees) to assess the cervix separately. NACO STI clinic protocols routinely include HIV testing with any STI workup because the two infections share transmission routes and the result changes management; testing is free and confidential at NACO clinics. For broader STI screening see STIs in Indian Women: Screening, Symptoms, Treatment, and NACO's Free Care.

Topical treatments are the gentlest first-line for small or moderate external warts and are often combined with later procedures if needed. Imiquimod 5 percent cream (Imiquad and other Indian brands, around four hundred to eight hundred rupees per sachet pack) is a patient-applied immune-response modifier that the woman applies to the warts three times a week at bedtime, washing it off after six to ten hours, for up to sixteen weeks. It works by triggering the local immune system to clear the virus and the warts. Mild redness and irritation are expected and tolerable; severe burning means stopping for a few days.

Podophyllotoxin or the related podophyllin solution is a plant-derived antimitotic that is applied directly to the warts to destroy the abnormal cells. Podophyllin (10 to 25 percent) is OB-applied in the clinic because of its strength and is washed off after one to four hours; it is available free at primary health centres and NACO STI clinics. Patient-applied podophyllotoxin 0.5 percent solution is used twice daily for three days, then four days off, for up to four cycles. Both forms work over four to six weeks and are not used in pregnancy.

Trichloroacetic acid (TCA) 80 to 90 percent is a chemical cauterant applied carefully to each wart by the doctor in the clinic, with neutralisation of any spilled acid using sodium bicarbonate. Several weekly sessions are usually needed and the cost at private clinics is around three hundred to eight hundred rupees per session. TCA is one of the few topical options considered safe in pregnancy. Across all topical options, the typical course is four to six weeks before deciding whether the warts have cleared, partially responded or need to be switched to a procedure.

When topical treatment is not enough, when warts are large or numerous, or when faster clearance is preferred, procedural removal at an OB-GYN or dermatology clinic is the next step. Cryotherapy with liquid nitrogen freezes the wart and destroys the abnormal cells; it is applied with a probe or spray, takes a few minutes per wart, causes a brief sharp sting, and usually needs two to four sessions a week or two apart. Cost at private clinics is around five hundred to two thousand rupees per session and the technique is widely available in Indian dermatology and gynaecology practices.

Electrocautery uses a small electric current to burn off the warts under local anaesthesia, takes ten to twenty minutes for a small to moderate area, and is typically a single session with a recovery period of one to two weeks. Cost at private clinics is around one thousand five hundred to four thousand rupees. Laser ablation (typically CO2 laser) vaporises the warts precisely and is preferred for hard-to-reach areas, larger clusters, vaginal or cervical warts, and recurrent disease that has not responded to other methods. Cost at major hospitals and dermatology chains such as Apollo Kaya and Oliva ranges from five thousand to fifteen thousand rupees per session.

Surgical excision under local or short general anaesthesia is reserved for very large warts, those needing tissue for biopsy, or cases where other methods have failed. The choice between cryo, electrocautery, laser and excision depends on wart size and location, the doctor's available equipment, cost considerations and pregnancy status, and is made together with the treating clinician. Most women need a combination of topical and procedural approaches over the full course of treatment.

Genital warts in pregnancy behave differently because of the immune and hormonal changes of pregnancy: they often grow more rapidly, may become larger and more vascular than usual, and can occasionally form bulky clusters that interfere with comfort or with a planned vaginal delivery. The good news is that most warts in pregnancy can still be managed, and the small risk of transmission to the baby during delivery (causing rare juvenile-onset recurrent respiratory papillomatosis) does not by itself require a caesarean — vaginal delivery is appropriate for most women with genital warts unless the warts are large enough to physically obstruct the birth canal or to bleed heavily.

Treatment in pregnancy uses only the safe options: trichloroacetic acid (TCA) applied in the clinic, cryotherapy, electrocautery and surgical excision under local anaesthesia. These are all considered safe and are routinely used by OB-GYNs when wart removal is needed before delivery. Podophyllin podophyllotoxin and imiquimod are AVOIDED in pregnancy because of theoretical or proven risks to the baby; podophyllin in particular can cause fetal harm if absorbed and is contraindicated.

The OB will usually monitor warts through pregnancy and decide whether treatment is needed before delivery based on size, location and bleeding. Many small warts are left alone in pregnancy because they often regress spontaneously in the weeks after delivery as hormones settle. Open conversation with the OB about the warts, the delivery plan and any visible growth between visits is the right approach.

Partner involvement matters in two practical ways. First, the male partner should be examined for visible warts on the penis scrotum perianal area or in the mouth, and any visible warts should be treated, because untreated visible warts in one partner are a continued source of skin-to-skin viral load to the other. Most male partners can be examined and treated by a dermatologist or urologist with the same options (cryotherapy, electrocautery, imiquimod, podophyllin); cost ranges are similar. Second, both partners should know that condoms reduce but do not eliminate transmission, that the virus can be spread without visible warts, and that long-term mutual monogamy with a previously uninfected partner is the most effective behavioural reduction.

The HPV vaccine is the single most effective prevention tool and is the recommendation that changes outcomes most. In India two vaccines are available: Cervavac, the Indian-made quadrivalent vaccine from Serum Institute, which protects against HPV types 6, 11, 16 and 18 and costs around two thousand to two thousand five hundred rupees per dose; and Gardasil, the imported nine-valent vaccine, which protects against HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 and costs around three thousand to four thousand five hundred rupees per dose. Both vaccines prevent the wart-causing types 6 and 11 as well as the main cancer-causing types.

The vaccine is most effective when given before any HPV exposure, which means before sexual debut, and the Indian schedule recommends it from age 9 onwards with two doses (six months apart) for under-15s or three doses for older adolescents and adults. Vaccination is still worthwhile after exposure or even after a genital warts diagnosis because protection against the strains the woman has not yet acquired is still gained. For full vaccine details see The HPV Vaccine in India: Cervavac, Gardasil, and What Every Family Should Know.

Recurrence after successful clearance of visible warts is common and expected rather than a sign of treatment failure. Between thirty and seventy percent of women have a recurrence within six months of completing treatment, because clearing the visible warts does not always clear the underlying HPV from the surrounding skin. The immune system continues to work on the latent virus in the background, and most women eventually clear the infection completely, with around ninety percent reaching virological clearance within two years.

Recurrent warts are managed with the same options used for the first episode — usually a combination of topical imiquimod or podophyllin and procedural removal — and most recurrences respond as well as the first treatment. Recurrences that are persistent, multiple or unusually aggressive deserve a more careful look. A dermatologist or OB-GYN with experience in HPV disease will check for the wider pattern, may consider extended imiquimod courses, and may request HIV testing because immunosuppression from HIV or other causes is a known driver of treatment-resistant warts.

The long-term outlook for a woman with genital warts is good. The infection clears in the great majority within one to two years, recurrences become less frequent over time, and the warts do not progress to cancer. The cancer risk that comes from any concurrent high-risk HPV infection is addressed separately through routine cervical screening with Pap smear and HPV DNA testing on the schedule set by the OB-GYN. For broader STI follow-up see STIs in Indian Women: Screening, Symptoms, Treatment, and NACO's Free Care.